{"id":"magnesium-esomeprazole","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Diarrhea"},{"rate":"2-5","effect":"Nausea"},{"rate":"2-5","effect":"Abdominal pain"},{"rate":"2-5","effect":"Constipation"},{"rate":"1-2","effect":"Hypomagnesemia (with long-term use)"}]},"_chembl":null,"_dailymed":{"setId":"4db9f4b8-b6df-f6e9-e063-6294a90a9f60","title":"ESOMEPRAZOLE MAGNESIUM CAPSULE, DELAYED RELEASE [AVPAK]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Esomeprazole is the active S-enantiomer of omeprazole that irreversibly binds to and inhibits the H+/K+-ATPase enzyme (proton pump) on the secretory surface of gastric parietal cells. This blocks the final step of gastric acid production, significantly reducing intragastric acidity. The magnesium salt formulation improves solubility and bioavailability compared to the free base.","oneSentence":"Magnesium esomeprazole inhibits the proton pump in gastric parietal cells, reducing gastric acid secretion.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:02.157Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastroesophageal reflux disease (GERD)"},{"name":"Peptic ulcer disease"},{"name":"Zollinger-Ellison syndrome"},{"name":"Prevention of NSAID-induced ulcers"}]},"trialDetails":[{"nctId":"NCT07312370","phase":"PHASE4","title":"Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing","status":"NOT_YET_RECRUITING","sponsor":"LanZhou University","startDate":"2026-04-20","conditions":"Early Gastric Cancer, Gastric Dysplasia, Gastric Neoplasms","enrollment":120},{"nctId":"NCT07294846","phase":"PHASE1","title":"Drug Interaction Study on Linaprazan Glurate Capsules","status":"COMPLETED","sponsor":"Jiangsu Sinorda Biomedicine Co., Ltd","startDate":"2025-09-08","conditions":"Healthy Volunteers, Patients","enrollment":56},{"nctId":"NCT01471925","phase":"PHASE3","title":"Study Comparing Esomeprazole Associated With Sodium Bicarbonate From Eurofarma and Esomeprazole in Treatment of Gastroesophageal Reflux Disease ESOBIC","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"","conditions":"Gastroesophageal Reflux Disease","enrollment":""},{"nctId":"NCT06850480","phase":"PHASE3","title":"A Phase III Clinical Trial for Efficacy and Safety Evaluation of JP-1366 Tablets on Reflux Esophagitis","status":"RECRUITING","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2024-12-05","conditions":"Reflux Esophagitis (RE)","enrollment":356},{"nctId":"NCT06823791","phase":"PHASE1, PHASE2","title":"Furazolidone Quadruple Regimen Eradicate H. Pylori Infection","status":"COMPLETED","sponsor":"Liaocheng People's Hospital","startDate":"2022-08-01","conditions":"Helicobacter Pylori Infection, Eradication","enrollment":493},{"nctId":"NCT01544114","phase":"PHASE4","title":"A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-04","conditions":"Juvenile Idiopathic Arthritis (JIA)","enrollment":46},{"nctId":"NCT06233097","phase":"PHASE1","title":"Esomeprazole Magnesium Dihydrate 40 mg Tablets Relative to Nexium 40 mg Tablets Under Fasting Condition","status":"UNKNOWN","sponsor":"Bio-innova Co., Ltd","startDate":"2024-08-29","conditions":"Healthy Subjects","enrollment":30},{"nctId":"NCT06233149","phase":"PHASE1","title":"Esomeprazole Magnesium Dihydrate 40 mg Tablets Relative to Nexium 40 mg Tablets Under Fed Condition","status":"UNKNOWN","sponsor":"Bio-innova Co., Ltd","startDate":"2024-10-01","conditions":"Healthy Subjects","enrollment":40},{"nctId":"NCT05577468","phase":"PHASE3","title":"Efficacy and Safety of Tegoprazan Versus Esomeprazole-containing Bismuth Quadruple Therapy for Eradication of Helicobacter Pylori","status":"COMPLETED","sponsor":"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.","startDate":"2022-10-30","conditions":"Helicobacter Pylori Infection","enrollment":561},{"nctId":"NCT03985319","phase":"PHASE1","title":"Clinical Trial to Assess the PK/PD of YYD601 20mg After Oral Administration if Healthy Adult Subjects (Phase1)","status":"COMPLETED","sponsor":"Yooyoung Pharmaceutical Co., Ltd.","startDate":"2019-07-08","conditions":"GERD","enrollment":28},{"nctId":"NCT03967886","phase":"PHASE3","title":"Clinical Trial to Assess the Efficacy and Safety of YYD601 in NERD Patients","status":"COMPLETED","sponsor":"Yooyoung Pharmaceutical Co., Ltd.","startDate":"2019-04-10","conditions":"Non-erosive Reflux Disease","enrollment":170},{"nctId":"NCT03943992","phase":"PHASE3","title":"Clinical Trial to Assess the Efficacy and Safety of YYD601 in the Treatment of Esophageal Reflux Disease (ERD)","status":"COMPLETED","sponsor":"Yooyoung Pharmaceutical Co., Ltd.","startDate":"2019-01-29","conditions":"Erosive Esophagitis","enrollment":170},{"nctId":"NCT00978016","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)","status":"COMPLETED","sponsor":"XenoPort, Inc.","startDate":"2009-09","conditions":"Gastroesophageal Reflux Disease","enrollment":460},{"nctId":"NCT04696783","phase":"PHASE3","title":"The Effect of PPI in Preventing Gastroesophageal Reflux Disease of Seafarers","status":"UNKNOWN","sponsor":"Fifth Affiliated Hospital, Sun Yat-Sen University","startDate":"2021-07","conditions":"Gastroesophageal Reflux Disease","enrollment":92},{"nctId":"NCT03488147","phase":"PHASE2","title":"Whether Proton Pump Inhibitors, Administered Prior to or After Surgery, Can Reduce the Incidence and/or Severity of Difficulty Swallowing Foods and/or Liquids,Following Anterior Cervical Surgery","status":"WITHDRAWN","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2020-07","conditions":"Dysphagia, GERD, Degenerative Joint Disease","enrollment":""},{"nctId":"NCT00443963","phase":"PHASE4","title":"Total Antioxidant Effects of Esomeprazole in Dyspeptic Patients Receiving Non-steroidal Anti-inflammatory Drugs","status":"WITHDRAWN","sponsor":"Medstar Health Research Institute","startDate":"2006-12","conditions":"Dyspepsia","enrollment":""},{"nctId":"NCT04034641","phase":"PHASE4","title":"Effect of Probiotics on Helicobacter Pylori Eradication","status":"UNKNOWN","sponsor":"Hangzhou Grand Biologic Pharmaceutical, Inc.","startDate":"2019-06-17","conditions":"Helicobacter Pylori Eradication","enrollment":238},{"nctId":"NCT02637557","phase":"PHASE2","title":"A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD)","status":"COMPLETED","sponsor":"Ironwood Pharmaceuticals, Inc.","startDate":"2016-03-01","conditions":"Gastroesophageal Reflux Disease","enrollment":282},{"nctId":"NCT03211143","phase":"PHASE1","title":"A Study to Compare PK, PD and Safety of CKD-381 in Healthy Subjects","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2017-06-20","conditions":"GERD","enrollment":41},{"nctId":"NCT02479581","phase":"PHASE2","title":"The Safety and Efficacy of the Enhanced Recovery After Surgery(ERAS)Applied on Cardiac Surgery With Cardiopulmonary Bypass","status":"COMPLETED","sponsor":"Xiangya Hospital of Central South University","startDate":"2015-07","conditions":"Valvular Heart Disease","enrollment":226},{"nctId":"NCT02708355","phase":"PHASE4","title":"Pilot Study To Investigate The Association Between Acid Control And Heartburn Symptoms After Proton Pump Inhibitor Treatment","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-01","conditions":"Heartburn","enrollment":55},{"nctId":"NCT02680119","phase":"PHASE1","title":"BE of Torrent's Esomeprazole Mg DR Capsules","status":"COMPLETED","sponsor":"Torrent Pharmaceuticals Limited","startDate":"2011-05","conditions":"Healthy","enrollment":56},{"nctId":"NCT02680132","phase":"PHASE1","title":"Bioequivalence Study of Torrent Pharmaceutical Ltd's Esomeprazole Magnesium Delayed Release Capsules","status":"COMPLETED","sponsor":"Torrent Pharmaceuticals Limited","startDate":"2011-05","conditions":"Healthy","enrollment":56},{"nctId":"NCT02659683","phase":"PHASE1","title":"Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Esomeprazole Magnesium DR Capsules Under Fasting Conditions","status":"COMPLETED","sponsor":"Torrent Pharmaceuticals Limited","startDate":"2011-05","conditions":"Healthy Subjects","enrollment":54},{"nctId":"NCT01669811","phase":"PHASE3","title":"Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-08","conditions":"Refractory Reflux Esophagitis","enrollment":1398},{"nctId":"NCT00660660","phase":"PHASE4","title":"Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-04","conditions":"Gastroesophageal Reflux Disease","enrollment":276},{"nctId":"NCT00474903","phase":"PHASE2","title":"Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-04","conditions":"Barrett Esophagus, Esophageal Cancer","enrollment":122},{"nctId":"NCT00317044","phase":"PHASE2","title":"Safety and Efficacy Study to Determine Anti-Asthmatic Effect of Esomeprazole Magnesium; Nexium Reflux Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-04","conditions":"Asthma, GERD","enrollment":961},{"nctId":"NCT00468559","phase":"PHASE3","title":"Phase 3/Safety & Efficacy of Esomeprazole in Infants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-04","conditions":"Gastroesophageal Reflux Disease (GERD)","enrollment":98},{"nctId":"NCT01964131","phase":"PHASE1","title":"BE Study Between a Capsule and a Sachet Formulation of D961H by Pharmacodynamics in Japanese Healthy Male Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-10","conditions":"Gastric Ulcer, Duodenal Ulcer, Anastomotic Ulcer","enrollment":34},{"nctId":"NCT01370538","phase":"PHASE3","title":"Efficacy of Esomeprazole in Patients With Frequent Heartburn","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-08","conditions":"Heartburn","enrollment":341},{"nctId":"NCT01370525","phase":"PHASE3","title":"Efficacy of Esomeprazole in Patients With Frequent Heartburn","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-08","conditions":"Heartburn","enrollment":340},{"nctId":"NCT01142128","phase":"PHASE1","title":"Viokase 16, Viokase16 Plus Nexium and Nexium Alone","status":"TERMINATED","sponsor":"University of Florida","startDate":"2009-02","conditions":"Chronic Pancreatitis","enrollment":12},{"nctId":"NCT01135472","phase":"PHASE1","title":"Plasm Gastrin Concentrations in Response to Nexium Administration in Healthy Volunteers","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2010-03","conditions":"Healthy","enrollment":10},{"nctId":"NCT00734097","phase":"PHASE4","title":"A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-11","conditions":"Gastroesophageal Reflux Disease","enrollment":314},{"nctId":"NCT01132638","phase":"PHASE3","title":"Pantoprazole Magnesium 40 mg Versus Esomeprazole 40 mg in Patients With Erosive Gastroesophageal Reflux Disease","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-08","conditions":"GERD","enrollment":713},{"nctId":"NCT00637559","phase":"PHASE4","title":"Barrett's Esophagus - 315 - 3 Way Cross-Over","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-03","conditions":"Barrett's Esophagus","enrollment":50},{"nctId":"NCT00343161","phase":"PHASE4","title":"Symptom Adapted Therapy in GERD Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-08","conditions":"Gastroesophageal Reflux Disease","enrollment":441},{"nctId":"NCT00637845","phase":"PHASE4","title":"Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease (GERD)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-06","conditions":"Heartburn, Gastroesophageal Reflux Disease","enrollment":248},{"nctId":"NCT00079833","phase":"PHASE3","title":"Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-11","conditions":"Zollinger-Ellison Syndrome","enrollment":25},{"nctId":"NCT00206024","phase":"PHASE4","title":"Acid-Associated Heartburn Symptoms and Dose of Esomeprazole","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-11","conditions":"Heartburn","enrollment":330},{"nctId":"NCT00641602","phase":"PHASE4","title":"A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment With Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients With Moderate or Severe Erosive Esophagitis","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-12","conditions":"Erosive Esophagitis","enrollment":1000},{"nctId":"NCT00206180","phase":"PHASE4","title":"NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-06","conditions":"Erosive Esophagitis, Reflux Esophagitis, Gastroesophageal Reflux Disease","enrollment":120},{"nctId":"NCT00629512","phase":"PHASE3","title":"Prevention of Gastric Ulcers","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2001-03","conditions":"NSAID Associated Gastric Ulcers","enrollment":504},{"nctId":"NCT00687245","phase":"PHASE1","title":"Pharmacokinetic Study of Esomeprazole Magnesium in Patients 1 to 11 Years-Old With Endoscopically-Proven Gastroesophageal Reflux Disease (GERD)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-08","conditions":"Endoscopically-Proven GERD, Reflux","enrollment":40}],"_emaApprovals":[],"_faersSignals":[{"count":57,"reaction":"ACUTE KIDNEY INJURY"},{"count":44,"reaction":"HYPONATRAEMIA"},{"count":42,"reaction":"DIARRHOEA"},{"count":39,"reaction":"DRUG INTERACTION"},{"count":38,"reaction":"NAUSEA"},{"count":30,"reaction":"OFF LABEL USE"},{"count":27,"reaction":"ASTHENIA"},{"count":27,"reaction":"THROMBOCYTOPENIA"},{"count":26,"reaction":"VOMITING"},{"count":25,"reaction":"DRUG INEFFECTIVE"}],"_approvalHistory":[],"publicationCount":127,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Magnesium Esomeprazole","genericName":"Magnesium Esomeprazole","companyName":"Takeda","companyId":"takeda","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Magnesium esomeprazole inhibits the proton pump in gastric parietal cells, reducing gastric acid secretion. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Zollinger-Ellison syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}